Commentary|Articles|February 5, 2026

Leading Breast Radiologists Discuss the Recent Lancet Study on AI and Interval Breast Cancer

Author(s)Jeff Hall

Wendie Berg, M.D., Stamatia Destounis, M.D., and Amy Patel, M.D., share their thoughts and perspectives on key findings from the Lancet mammography study on AI and interval breast cancer, and how they have incorporated AI into their practices.

Recently reported results from the randomized controlled Mammography Screening with Artificial Intelligence (MASAI) trial suggest that adjunctive AI may provide a viable role in mammography triage with researchers noting significant decreases in interval breast cancer rates in a cohort of 105,915 women.

Related to this article

Key Sessions of Interest for Radiologists at the Upcoming HLTH USA Conference
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.